clinical trial · NCT06227377
QTX3034 in Patients With KRAS G12D Mutation
Solid TumorsQTX3034Cetuximab
brief summary
Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab.
started
Feb 5, 2024
primary completion
Apr 1, 2027
completion
Apr 1, 2027
last updated
Dec 24, 2025
official title
A Phase 1 Trial Evaluating the Safety, Tolerability, PK, and Efficacy of QTX3034 in Patients With Solid Tumors With KRASG12D Mutation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol